PTC Therapeutics, Inc. (PTCT) Closes UP+88% Friday on CHMP News
PTC Therapeutics, Inc. (PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients five years and older. In connection with the renewal, the marketing authorization will include a specific obligation to conduct an additional long-term post-authorization trial.
“We are pleased with this outcome which took into account all available data for Translarna,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. “This decision reflects the benefit that Translarna is having for patients suffering from nonsense mutation Duchenne muscular dystrophy.”
PTC Therapeutics, Inc. (PTCT) Shares Closesd UP+88% Friday, November 11th, 2016.
Please view a full list of Disclaimers which are available at www.vistapglobal.com/disclaimer/